Results 21 to 30 of about 4,022 (166)
Microbiology Spectrum, 2023 In this study, we aimed to comparatively evaluate the in vitro activity of cefiderocol versus other antimicrobials against a well-characterized collection of metallo-beta-lactamase (MBL)-producing Gram-negative bacilli (MBL-GNB) isolates from hospitals ...
M. Delgado-Valverde +4 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2021 : Objectives: The incidence of antimicrobial resistance in Europe is rising. Cefiderocol is approved in Europe for treatment of aerobic Gram-negative bacterial (GNB) infections in adults with limited treatment options. We report the in vitro activity of
Emilia Cercenado +5 more
doaj +1 more source
Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol [PDF]
Clinical Pharmacokinetics, 2021 Cefiderocol is a new broad-spectrum cephalosporin antibiotic with promising activity against various Gram-negative bacteria including carbapenem-resistant strains. A chlorocatechol group in the C-3 side chain provides cefiderocol with a siderophore activity, improving its stability against β-lactamases and facilitating the transportation of cefiderocol
Muhammad Bilal +5 more
openaire +2 more sources
Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance
Nature Communications, 2023 The rapid emergence of antimicrobial resistance (AMR) pathogens highlights the urgent need to approach this global burden with alternative strategies. Cefiderocol (Fetroja®) is a clinically-used sideromycin, that is utilized for the treatment of severe ...
Chenyuan Wang +9 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2021 Objectives: The aim of this study was to investigate the clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections. Methods: The PubMed, Embase and Cochrane Library databases as well as the clinical trials registries of ...
Shun-Chung Hsueh +4 more
doaj +1 more source
An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms
Life, 2023 Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat (DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas aeruginosa, CR Acinetobacter baumannii, and CR- and third-generation-cephalosporins-
Sara Domingues +3 more
doaj +1 more source
Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
Antibiotics, 2023 Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms.
Monirul I. Sajib +2 more
doaj +1 more source
Clinical experience of cefiderocol
Revista Española de Quimioterapia, 2022 Infections by antibiotic-resistant microorganisms could be considered a “stealth pandemic” that we fight daily in most hospitals. Some estimates suggest that today 700,000 deaths per year can be attributed to antimicrobial resistance. By the year 2050, it is estimated that this will increase to ten million deaths per year as a result of infections by ...
openaire +3 more sources
Emerging Infectious Diseases, 2023 Cefiderocol resistance is increasingly reported in New Delhi metallo-β-lactamase–producing Enterobacterales. Genomic and phenotypic analysis of Escherichia coli sequence type 361, a primary clone causing carbapenemase spread in France, revealed ...
Agnès B. Jousset +11 more
doaj +1 more source
Microbiology Spectrum, 2023 Cefiderocol and aztreonam-avibactam (ATM-AVI) both had activity against carbapenem-resistant Gram-negative bacilli, including those that produce metallo-β-lactamases (MBLs).
Yu-Shan Huang +3 more
doaj +1 more source